These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25846403)

  • 1. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein.
    Huang T; Dennis A; Meschino WS; Rashid S; Mak-Tam E; Cuckle H
    Prenat Diagn; 2015 Jul; 35(7):709-16. PubMed ID: 25846403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA.
    Johnson J; Pastuck M; Metcalfe A; Connors G; Krause R; Wilson D; Cuckle H
    Prenat Diagn; 2013 Nov; 33(11):1044-9. PubMed ID: 23836291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service.
    Carmichael J; Krantz D; Liu HP; Janik D; Hallahan T
    Prenat Diagn; 2015 Jul; 35(7):703-8. PubMed ID: 25846256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Down syndrome screening performance using first-trimester serum markers.
    Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
    Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome.
    Donalson K; Turner S; Morrison L; Liitti P; Nilsson C; Cuckle H
    Prenat Diagn; 2013 May; 33(5):457-61. PubMed ID: 23529706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First trimester maternal serum placental growth factor in trisomy 21 pregnancies.
    Cowans NJ; Stamatopoulou A; Spencer K
    Prenat Diagn; 2010 May; 30(5):449-53. PubMed ID: 20301202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012600. PubMed ID: 28295158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early first-trimester maternal serum placental growth factor in trisomy 21 pregnancies.
    Cowans NJ; Stamatopoulou A; Tørring N; Spencer K
    Ultrasound Obstet Gynecol; 2011 May; 37(5):515-9. PubMed ID: 21105022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester screening for trisomy 21 using alpha-fetoprotein.
    Bredaki FE; Wright D; Matos P; Syngelaki A; Nicolaides KH
    Fetal Diagn Ther; 2011; 30(3):215-8. PubMed ID: 21952001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland.
    Peuhkurinen S; Laitinen P; Honkasalo T; Ryynanen M; Marttala J
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):769-74. PubMed ID: 23369035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
    Nicolaides KH; Wright D; Poon LC; Syngelaki A; Gil MM
    Ultrasound Obstet Gynecol; 2013 Jul; 42(1):41-50. PubMed ID: 23744626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
    Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining fetal nuchal fold thickness with second-trimester biochemistry to screen for trisomy 21.
    Borrell A; Mercade I; Casals E; Borobio V; Seres A; Soler A; Fortuny A; Cuckle H
    Ultrasound Obstet Gynecol; 2007 Dec; 30(7):941-5. PubMed ID: 18000942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate biochemical parameters in first-trimester screening for Down syndrome.
    Cuckle HS; van Lith JM
    Prenat Diagn; 1999 Jun; 19(6):505-12. PubMed ID: 10416963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.
    Zaragoza E; Akolekar R; Poon LC; Pepes S; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Apr; 33(4):382-6. PubMed ID: 19277983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.